A股異動 | 南新制藥(688189.SH)漲逾18% 擬購買興盟蘇州全部股份
格隆匯11月9日丨南新制藥(688189.SH)復牌以漲停價開盤後回落,現報59.61元,漲幅18.27%,最新總市值83.45億,換手率7.8%。公司昨日公告稱,擬通過發行股份及支付現金的方式購買興盟蘇州全部股份。標的資產預估值為不超過26.71億元,在研產品包括4個生物創新藥和5個生物類似藥,覆蓋抗感染、腫瘤、自身免疫性疾病等領域,本次交易有利於上市公司豐富在研品種數量,拓寬疾病覆蓋領域,打造研發進度梯次有序的具備一定競爭力的產品組合,為企業長期快速發展提供充足動力。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.